Table 1.
Characteristics of included studies
| Author; Year | Country | Study years | Study design | Setting | CRs MIC /mg/L |
Type of infection | Male/ Female | Age (years) | Treatment regimen | Sample size (PXs vs. Non-PXs) | Route of colistin | APACHE II score (mean) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polymyxins group | Non-polymyxins group | ||||||||||||
| Trottier 2007 [27] | USA | 2004–05 | RS | MIX | NA | Mixb | 83/33 | 17 ~ 90 | COL | AMK; FEP; CPF; DOX; IMP; MNO; TZP | 96 vs. 20 |
IV/IH/IV+ IH/IV + IT |
NR |
| Betrosian 2008 [20] | Greece | NA | RCT | ICU | NA | VAP | 14/14 | adult | COL | SAM | 15 vs. 13 | IV | 14 |
| Lopez-Cortes 2014 [23] | Spain | 2010 | PS | NA | ≥32 | RT/SS/SST UT/IAI/CNS OA/Bm | NA | >18 |
COL; COL+TGC; COL+CRs; COL+SUL; COL+AG; COL+RIF; COL+TGC + AG; COL+TGC+ CRs + AG |
CRs; TGC; SUL; TCY; CRs + TGC; CRs + AG; TGC + RIF; TGC + AG; TGC + CRs + RIF |
52 vs. 12 | IV | NA |
| Ozvatan 2016 [24] | Turkey | 1996–2010 | RS | NA | NA | VAP | NA | ≥18 | COL; COL+OTH | M/I; SAM; CSL; OTH | 29 vs. 187 | IV | NA |
| Zalts 2016 [14] | Israel | 2008–09 | RS | ICU | NA | VAP | 70/28 | >18 | COL | SAM | 66 vs. 32 | IV | 17.5 |
| Pan 2018 [25] | China | 2013–17 | RCS | NA | NA | ICI | 30/31 | >18 | PB+ CTR |
M/I + AMK; M/I + TGC; M/I + CSL; M/I + TGC + CSL; CSL; CSL + AMK; |
23 vs. 38 | IV + IT | 18 |
| Khalili 2018 [21] | Iran | 2015–17 | RCT | ICU | ≥0.08 | VAP | 35/12 | 18 ~ 75 | MEM + COL | MEM + SAM | 24 vs.23 | IV | NA |
| Liang 2018 [22] | Taiwan | 2010–15 | RS | MIX | NA | Pmn | 167/71 | >20 | TGC + COL | TGC; TGC + OTH; SUL; SUL + OTH | 110 vs. 128 | IV/IV+ IH | 23 |
| Sipahi 2018 [26] | Turkey & France | 2007–16 | RS | ICU | NA | Meg | 12/8 | >18 | TGC + COL |
TGC + NET; TGC + AMK; TGC + MEM; TGC |
8 vs. 12 | IV/ IV + IT | NA |
| Chusri 2019 [13] | Thailand | 2012–17 | RS | MIX | ≥16 | IAI | 16/12 | >18 | TGC + COL | TGC | 14 vs. 14 | IV | 15/median |
| Raz-Pasteur 2019 [19] | Israel | 2013–15 | RCS | MIX | NA | Pmn/SST/Bm |
62/21 72/40 |
Any | COL |
SAM; TMP-SMX |
59 vs. 24 59 vs. 53 |
IV | NA |
AG aminoglycosides, AMK amikacin, Bm bacteremia, CNS central nervous system, COL colistin, CPF ciprofloxacin, CRs carbapenems, CSL cefoperazone-sulbactam, CTR ceftriaxone, DOX doxycycline, FEP cefepime, FQs fluoroquinolones, IAI intra-abdominal infection, ICI intracranial infection, ICU intensive care unit, IH inhaled, IMP imipenem, IT intrathecal/intracerebral, IV intravenous, Meg meningitis, MEM meropenem, M/I meropenem/imipenem, MIC minimum inhibitory concentration, MIX intensive care unit and hospital, MNO minocycline, NA not available, NET netilmicin, OA osteoarticular, OTH other antibiotics, PB polymyxin B, PCS prospective cohort study, Pmn pneumonia, PS prospective study, PXs polymyxins, RCS retrospective cohort study, RCT random clinical trial, RIF rifampicin, RS retrospective study, RT respiratory tract, SAM ampicillin-sulbactam, SST skin and soft tissue, SUL sulbactam, TCY tetracycline, TGC tigecycline, TMP-SMX trimethoprim-sulfamethoxazole, TZP piperacillin-tazobactam, UT urinary tract, VAP ventilator-associated pneumonia, vs. versus